- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 152121-30-7] SB 202190
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-10295 |
| Brand: | MCE |
| CAS: | 152121-30-7 |
Overview
| MDL | MFCD00941964 |
|---|---|
| Molecular Weight | 331.34 |
| Molecular Formula | C20H14FN3O |
| SMILES | FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2)C=C1 |
57 Publications Citing Use of MCE
- [1]Cell Res. 2020 Jul;30(7):574-589.
- [2]Immunity. 19 October 2022.
- [3]Mol Cancer. 2023 Jan 24;22(1):17.
- [4]Proc Natl Acad Sci U S A. 2023 Jan 31;120(5):e2213777120.
- [5]Cell Mol Gastroenterol Hepatol. 2022 Oct 21;S2352-345X(22)00222-3.
- [6]Cell Chem Biol. 2022 Jun 9;S2451-9456(22)00201-X.
- [7]Cancer Lett. 2022 Jul 1;537:215678.
- [8]J Invest Dermatol. 2020 Sep 9;S0022-202X(20)32055-8.
- [9]Sensor Actuat B-Chem. 2021, 128991.
- [10]BMC Med. 2021 Oct 15;19(1):247.
- [11]Cell Death Dis. 2022 Jul 15;13(7):615.
- [12]Cell Death Dis. 2022 Jun 9;13(6):540.
- [13]Cell Death Dis. 2021 Nov 13;12(11):1079.
- [14]Cell Death Dis. 2020 Sep 1;11(8):713.
- [15]Cell Biol Toxicol. 2021 Oct 25.
- [16]Free Radic Biol Med. 2021 Apr 15;S0891-5849(21)00222-7.
- [17]Cancers (Basel). 2021 Feb 28;13(5):1011.
- [18]J Neuroinflammation. 2018 Oct 19;15(1):291.
- [19]J Neuroinflammation. 2017 Nov 25;14(1):228.
- [20]EBioMedicine. 2015 Nov 19;2(12):1944-56.
- [21]Am J Cancer Res. 2022 Jul 15;12(7):3405-3421.
- [22]Oxid Med Cell Longev. 2017;2017:7426458.
- [23]J Chem Inf Model. 2021 Jul 21.
- [24]J Cell Mol Med. 2020 Jul;24(14):8151-8165.
- [25]iScience. 2021 Jul 10;24(8):102845.
- [26]Phytomedicine. 8 September 2021, 153740.
- [27]J Cell Biochem. 2019 Mar;120(3):3898-3910.
- [28]J Agric Food Chem. 2019 Aug 14;67(32):9009-9021.
- [29]Mol Ther Oncolytics. 5 August 2022.
- [30]Sci Rep. 2016 Jul 22;6:30146.
- [31]Int Immunopharmacol. 2021 Sep 22;100:108170.
- [32]Life Sci. 2020 Nov 15;261:118351.
- [33]Life Sci. 2020 Jul 15;253:117730.
- [34]Exp Cell Res. 2022 Oct 4;113374.
- [35]Int J Mol Med. 2017 Jul;40(1):164-174.
- [36]Int J Mol Med. 2017 Jan;39(1):71-80.
- [37]J Tissue Eng Regen Med. 2021 Sep 23.
- [38]Gene. 2020 Mar 17;741:144579.
- [39]Acta Biochim Biophys Sin (Shanghai). 2021 Aug 3;gmab108.
- [40]Acta Biochim Biophys Sin (Shanghai). 2019 Apr 1;51(4):365-374.
- [41]Innate Immun. 2020 Oct;26(7):580-591.
- [42]Mol Med Rep. 2020 Dec;22(6):4899-4908.
- [43]BMC Vet Res. 2020 May.
- [44]Evid-Based Compl Alt. 13 Jul 2022.
- [45]J Vasc Res. 2021 Jan 25;1-13.
- [46]Biosci Biotechnol Biochem. 2021 Jul 23;zbab136.
- [47]Patent. US20220389379A1.
- [48]Research Square Print. November 15th, 2022
- [49]bioRxiv. April 21, 2022.
- [50]bioRxiv. June 11, 2021.
- [51]Research Square Preprint. 2021 Nov.
- [52]Rep Biochem Mol Biol. 2021 Jul;10(2):314-326.
- [53]Reports of Biochemistry and Molecular Biology. 2021 Aug.
- [54]Research Square Preprint. 2021 Feb.
- [55]Research Square Preprint. 2021 Jan.
- [56]China Biotechnology. 2017, 37(12): 40-48.
- [57]Harvard Medical School LINCS LIBRARY
Summary
SB 202190 is a selective p38 MAP kinase inhibitor with IC 50 s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits [1] [2] . SB202190 induces autophagy [3] .
IC50 & Target
|
p38α 50 nM (IC 50 ) |
p38β2 100 nM (IC 50 ) |
In Vitro
SB 202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner
[1]
.
SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480)
[2]
.
In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SB 202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 4-week-old female BALB/c nude mice (bearing SW480 and RKO xenograft tumors) [2] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; daily for 10-12 days |
| Result: | Inhibition of tumor cell survival and tumor growth. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 301.80 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.0180 mL | 15.0902 mL | 30.1805 mL |
| 5 mM | 0.6036 mL | 3.0180 mL | 6.0361 mL |
| 10 mM | 0.3018 mL | 1.5090 mL | 3.0180 mL |
References
- [1] Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
- [2] Nemoto S, et al. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998 Jun 26;273(26):16415-20.
- [3] Grossi V, et al. Bay 43-9006 inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther. 2012 Dec;13(14):1471-81.
- [4] Yang S, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798.
- [5] Zhang Y, et al. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine. 2015 Nov 19;2(12):1944-56.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.